ClinicalTrials.gg
CompletedNCT04273087Updated Nov 18, 2022

Characterization of a Clinical Subpopulation With Autism Spectrum Disorder

An observational study in Autism Spectrum Disorder, sponsored by Stalicla SA. Completed at 1 site in United States. Open to participants aged 10 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-11-18.

Sponsored by Stalicla SA · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
236
Ages
10 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 773 studies in Autism Spectrum Disorder with a site in United States — 163 open to participants now, 203 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Enrollment
45th of 114
236 · median 132
Started
2020
with 44 others
Observational
114 of 773
23 open now
Registered
410th of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 45th largest by enrollment of the 114 observational ones that give a count, is one of 45 that started in 2020, is one of 114 observational ones, and was the 410th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

163 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 10 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

The main objective for this research study is to gather additional information to help confirm identification of new subgroups within the autism spectrum.

03

Conditions studied

  • Autism Spectrum Disorder
04

Who can participate

Ages eligible
10 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cincinnati Children's Hospital Primary Care Clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants previously diagnosed with ASD () supported by either autism diagnostic interview revised (ADI-R) or Autism Diagnostic Observation Scale (ADOS-2) scores
  • Available health records within the first 2 years of life
  • Participants must have a parent or reliable caregiver who agrees to provide information about the participant

Exclusion criteria

Exclusion Criteria:

  • Genetically identified ASD (syndromic form of autism, e.g. fragile X)
  • Episode of fever (i.e. ≥100.5 °F) or illness without fever (as judged by the Investigator), within 10 days before the study visit
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
236 participants (actual)
Patient registry
No

Interventions

  • OtherObservation

    Clinical signs and symptoms

06

What researchers measure

Primary outcomes

  1. Prevalence of non-behavioral phenotypical traits in sub-populations with Autism Spectrum Disorder (ASD)

    A questionnaire will be administered to collect non-behavioral traits and co-occurring conditions data of the participants

    Time frame: Day 0

07

Study locations

1 site
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Oct 2022, 28 months.

Of 112 observational studies under Autism Spectrum Disorder, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 120. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2020
First posted
Feb 17, 2020
StartActual
Jun 4, 2020
Primary completionActual
Oct 31, 2022
CompletionActual
Oct 31, 2022
Last update
Nov 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04273087
Lead sponsor
Stalicla SA
Responsible party
Sponsor
First posted
Feb 17, 2020
Start date
Jun 4, 2020
Primary completion
Oct 31, 2022
Completion
Oct 31, 2022
Last update
Nov 18, 2022

Study contacts

Craig A Erickson, MD
principal investigator · CCHMC

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion